|
Multiple Myeloma
|
0.050 |
Biomarker
|
disease |
BEFREE |
Starting from genome-wide gene-expression profiling to seek important NOTCH1 transcriptional targets, we identified DEP-domain containing mTOR-interacting protein (DEPTOR), which was previously shown to be important in multiple myeloma but remains functionally unclear in other hematological malignancies.
|
27593934 |
2017 |
|
Carcinogenesis
|
0.050 |
AlteredExpression
|
phenotype |
BEFREE |
However, the expression level of DEPTOR and its function in the tumorigenesis of osteosarcoma (OS) remain unknown.
|
28932123 |
2017 |
|
Tumor Cell Invasion
|
0.050 |
AlteredExpression
|
phenotype |
BEFREE |
Taken together, these results suggest that DEPTOR overexpression is necessary for the proliferation, migration, invasion, formation of vasculogenic mimicry, and survival of OS cells and may be a potential target for the treatment of OS.
|
28932123 |
2017 |
|
Carcinogenesis
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
DEP domain-containing mTOR-interacting protein (DEPTOR)/mammalian Target of Rapamycin (mTOR) signaling plays an important role in carcinogenesis.
|
27144580 |
2016 |
|
Carcinogenesis
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
DEPTOR regulation was also observed to be independent of HPV E6/E7 oncoproteins, but it might be a molecular co-factor contributing to cervical carcinogenesis.
|
26992219 |
2016 |
|
Tumor Cell Invasion
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
Furthermore, a series of assays conducted in DEPTOR knockout or ectopic expression in A549 cells confirmed that DEPTOR inhibited proliferation, migration, and invasion as well as the in vivo tumor growth of lung adenocarcinoma.
|
26896556 |
2016 |
|
Carcinogenesis
|
0.050 |
AlteredExpression
|
phenotype |
BEFREE |
Taken together, these data suggest that DEPTOR has a tumor suppressive activity against pancreatic cancer cells, and its loss of expression may contribute to pancreatic tumorigenesis.
|
25544749 |
2014 |
|
Tumor Cell Invasion
|
0.050 |
AlteredExpression
|
phenotype |
BEFREE |
The aim of this study was to investigate the expression of DEPTOR and mTORC1 activity (P-S6) in a subset of CRC patients and determine their relation to tumor differentiation, invasion, nodal metastasis and disease-free survival.
|
24969890 |
2014 |
|
Neoplasm Metastasis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
Functional experiments demonstrated that DEPTOR silencing inhibited the proliferation and mobility of HCC cells in vitro and suppressed tumor growth and metastasis of HCC cells in vivo.
|
31228948 |
2019 |
|
Colorectal Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Moreover, we provide a molecular basis for the synergistic combination of Wnt and mTOR inhibitors in treating colorectal cancer with elevated c-Myc.<b>Significance:</b> The mTOR inhibitor DEPTOR acts as a tumor promoter and could be a potential therapeutic target in colorectal cancer.<i></i>.
|
29666061 |
2018 |
|
Colorectal Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
The DEGs may function in CRC by interacting with other genes in the PPI network of the top 50 nodes, for example, DEP domain‑containing MTOR‑interacting protein (DEPTOR)‑CCND1, AURKA‑breast carcinoma amplified sequence‑1 (BCAS1), CCND1‑BCAS1, CCND1‑neural precursor cell expressed developmentally downregulated 9 (NEDD9) and CCND1‑mitogen‑activated protein kinase kinase 2 (MAP2K2).
|
28000901 |
2017 |
|
Colorectal Carcinoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
The present study indicates that regulation of DEPTOR/mTOR signaling may be an important mechanism for glutamine in prevention against the development of CAC.
|
27144580 |
2016 |
|
Neoplasm Metastasis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
Collectively, our findings highlight the dichotomous functions of Deptor in modulating the proliferation and survival of TNBCs during metastasis; they also implicate Deptor and its stimulation of survivin as essential components of TNBC resistance to chemotherapies and apoptotic stimuli.
|
25810016 |
2015 |
|
Colorectal Carcinoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Interestingly, P-S6 (S235/236) expression showed a significant negative association with the expression of DEPTOR in CRC (p=0.011, R= -0.279).
|
24969890 |
2014 |
|
Neoplasm Metastasis
|
0.040 |
AlteredExpression
|
phenotype |
BEFREE |
In contrast, the expression level of DEPTOR was correlated with low tumor histological grade (p=0.006), and negative nodal metastasis (p=0.001).
|
24969890 |
2014 |
|
Neoplasm Metastasis
|
0.040 |
AlteredExpression
|
phenotype |
BEFREE |
DEPTOR protein expression was significantly associated with lymph node status, extrathyroid extension and distant metastasis.
|
21643629 |
2011 |
|
Malignant Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
Moreover, we provide a molecular basis for the synergistic combination of Wnt and mTOR inhibitors in treating colorectal cancer with elevated c-Myc.<b>Significance:</b> The mTOR inhibitor DEPTOR acts as a tumor promoter and could be a potential therapeutic target in colorectal cancer.<i>Cancer Res; 78(12); 3163-75.©2018 AACR</i>.
|
29666061 |
2018 |
|
Primary malignant neoplasm
|
0.030 |
Biomarker
|
group |
BEFREE |
Moreover, we provide a molecular basis for the synergistic combination of Wnt and mTOR inhibitors in treating colorectal cancer with elevated c-Myc.<b>Significance:</b> The mTOR inhibitor DEPTOR acts as a tumor promoter and could be a potential therapeutic target in colorectal cancer.<i>Cancer Res; 78(12); 3163-75.©2018 AACR</i>.
|
29666061 |
2018 |
|
Malignant neoplasm of colon and/or rectum
|
0.030 |
Biomarker
|
disease |
BEFREE |
Moreover, we provide a molecular basis for the synergistic combination of Wnt and mTOR inhibitors in treating colorectal cancer with elevated c-Myc.<b>Significance:</b> The mTOR inhibitor DEPTOR acts as a tumor promoter and could be a potential therapeutic target in colorectal cancer.<i></i>.
|
29666061 |
2018 |
|
Malignant Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
DEPTOR knockdown partially rescued ROC1 knockdown-inhibited EMT and the ROC1-induced inhibition of cancer cell migration.
|
26742010 |
2016 |
|
Primary malignant neoplasm
|
0.030 |
Biomarker
|
group |
BEFREE |
DEPTOR knockdown partially rescued ROC1 knockdown-inhibited EMT and the ROC1-induced inhibition of cancer cell migration.
|
26742010 |
2016 |
|
Malignant neoplasm of colon and/or rectum
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
The present study indicates that regulation of DEPTOR/mTOR signaling may be an important mechanism for glutamine in prevention against the development of CAC.
|
27144580 |
2016 |
|
Malignant neoplasm of colon and/or rectum
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
DEPTOR expression negatively correlates with mTORC1 activity and tumor progression in colorectal cancer.
|
24969890 |
2014 |
|
Malignant Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
Furthermore, three independent laboratories including our own have demonstrated that the stability of DEPTOR is controlled by the SCF(β-TrCP) E3 ubiquitin ligase and deregulated DEPTOR destruction might contribute to hyperactivation of mTOR in pathologic conditions including cancer.
|
22745583 |
2012 |
|
Primary malignant neoplasm
|
0.030 |
Biomarker
|
group |
BEFREE |
Furthermore, three independent laboratories including our own have demonstrated that the stability of DEPTOR is controlled by the SCF(β-TrCP) E3 ubiquitin ligase and deregulated DEPTOR destruction might contribute to hyperactivation of mTOR in pathologic conditions including cancer.
|
22745583 |
2012 |